

29-05-2018

Ref/Colinz/Results-Q4/2017-18
To,
Department of Corporate Services
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

BSE STOCK CODE NO : 531210

Dear Sir,

Sub: Outcome of Board Meeting held today i.e. 28th May 2018 pursuant to

notice dated 22nd May 2018 and the agenda of the meeting as set out in the said notice.

I am pleased to inform you that the Board of Directors of Colinz Laboratories Limited (the "Company") has considered and approved the financial results for the quarter ended 31st March 2018. The results are as follows:

The Board has also approved the dividend for the quarter ended 31st March 2018. The dividend is payable to the shareholders of the Company who are entitled to receive the same.

The Board has also approved the appointment of the auditors for the year ending 31st March 2019.

Yours faithfully,

For the Board,

Secretary

Colinz Laboratories Limited

Mumbai

29-05-2018

29-05-2018



VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020, INDIA

TEL. : +91-22-2200 5933
+91-22-2200 5934
+91-22-6615 5599
+91-22-2206 3289

Web: www.cavoras.com

e-mail: office@cavoras.com
cavoras@gmail.com

Ref.: MA: 18 : CLL 1129

INDEPENDENT AUDITOR'S REPORT

To,
Board of Directors,
COLINZ LABORATORIES LIMITED

We have audited the accompanying statements of financial results of **COLINZ LABORATORIES LIMITED** for the year ended 31st March 2018, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR / CFD / FAC / 62 / 2016 dated July 5, 2016.

This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('Ind AS') prescribed u/s. 133 of the Companies Act, 2013 read with relevant rules thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to issue a Report on the Statement based on our audit. Attention is drawn to the fact that the figures for the quarter ended March 31, 2018 as reported in the Statement are the balancing figures in respect of the year ended March 31, 2018 and published year to date figures up to end of the third quarter of the relevant financial year. The figures up to end of the third quarter are only reviewed and not subject to audit.

We conducted our audit in accordance with the Standards on Auditing generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures.





VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

TEL. : +91-22-2200 5933
+91-22-2200 5934
+91-22-6615 5599
+91-22-2206 3289

Web. : www.cavoras.com

e-mail: office@cavoras.com

cavoras@gmail.com

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR / CFD / FAC / 62 / 2016 dated July 5, 2016 in this regard; and

(ii) give a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the Net Profit, Total comprehensive income and other financial information of the Company for the quarter ended March 31, 2018 as well as year to date results for the year ended March 31, 2018

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)

MAYUR A. VORA
PARTNER

(Membership No.: 030097)



PLACE: MUMBAI

DATED: 29 MAY 2018

COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078.

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2018

"(Rs. In Lakhs)"

		(Rs. in Lakhs)				
S. No.	Particulars	Audited	Un-audited	Audited	Audited	
		Quarter ended		YEAR ENDED		
		31-Mar-18	31-Dec-17	31-Mar-17	31-Mar-18	31-Mar-17
PART -I						
1	(a)Revenue from Operation	187.48	194.68	178.15	795.80	804.70
3	(b) Other Income	2.64	2.97	3.12	9.76	9.17
3	Total Income from Operation	190.12	197.65	181.27	805.56	813.87
4	Expenses					
	(a) Cost Of Material Consumed	6.45	67.15	6.57	145.37	129.55
	(b) Purchase of Stock in Trade	33.63	44.51	46.60	114.52	158.04
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	(4.24)	(44.01)	7.89	10.39	6.83
	(d) Employee Benefit Expenses	88.82	82.76	72.89	339.27	313.32
	(e) Finance Cost	2.82	1.49	3.61	8.38	11.79
	(f) Depreciation & Amortisation Expenses	5.53	5.53	6.62	22.11	26.50
	(g) Other Expenses	53.69	33.49	34.59	150.39	156.03
	Total Expenses	186.70	190.92	178.77	790.43	802.06
5	Profit /(Loss) Before exceptional items and tax (3-4)	3.42	6.73	2.50	15.13	11.81
6	Exceptional items	-	-	-	-	-
7	Profit /(Loss) before tax (5-6)	3.42	6.73	2.50	15.13	11.81
8	Tax Expenses (Provision for Taxation) Current tax					
	i) Current Tax	5.58	0.90	0.59	7.68	1.40
	ii) Deferred Tax	(9.13)	-	-	(9.13)	(3.70)
	iii) Tax for earlier years	1.37	-	-	1.37	-
	iv) MAT Credit of Earlier years	(7.85)	-	-	(7.85)	-
9	Profit /(Loss) for the period from continuing operations(7-8)	13.45	5.83	1.91	23.06	14.11
10	Profit /(Loss) for the period	13.45	5.83	1.91	23.06	14.11
Other Comprehensive Income (Net of Tax)						
A) Item that will not be reclassified to Profit or Loss Account						



STATEMENT OF ASSETS AND LIABILITIES				
Particulars			31-Mar-2018	31-Mar-2017
Non-Current Assets				
a) Property, Plant & Equipment			241.19	263.30
b) Capital Work-in progress			-	-
c) Intangible Assets			-	-
d) Financial Assets				
i) Investments			52.68	41.45
ii) Loans			-	-
iii) Other Financial Assets			-	-
e) Other Non Current Assets			110.46	127.93
Total Non-Current Assets			404.33	432.68
Current Assets				
a) Inventories			18.57	18.57

Non-Current Liabilities				
a) Financial Liabilities			72.33	100.04
b) Other Non-Current Liabilities				
Current Liabilities				
a) Financial Liabilities				
i) Borrowings			42.05	75.95
ii) Trade Payables			67.54	45.15
b) Other Current Liabilities			90.11	87.48
c) Current Provisions			11.88	6.04
Total Current Liabilities			211.58	214.62
TOTAL EQUITY AND LIABILITIES			959.00	967.48



NOTES TO THE FINANCIAL RESULTS :-

- 1) The consolidated financial results have been prepared in accordance with the Indian Accounting Standards (IND-AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- 2) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 29th May, 2018.
- 3) The Company has adopted IND-AS from 1-4-2017 and accordingly the Financial Results are prepared in accordance with the principles stated therein.
- 4) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment as defined by IND-AS.
- 5) Since duty on sales was included under revenue from operations and disclosed separately under expenses upto the reporting period ending 30th June 2017. Post Implementation of Goods and Service Tax (GST) from beginning of the quarter ended 30th September, 2017, revenue from operations is reported net of GST and hence to that extent is not comparable.
- 6) The reconciliation of net profit as reported under previous Generally Accepted Accounting Principles (Previous GAAP) and as per IND-AS for the year ended 31st March 2018 is given below:

Net Profit as per OLD INDIAN GAAP	23.06
(+)/(-) Impact of implementation of IND-AS	
Increase in fair value of Investments	(0.20)
Net Profit as per NEW GAAP	22.86

- 7) Previous figures have been regrouped/ rearranged / reclassified, wherever necessary as per IND-AS.

MUMBAI.
29th MAY, 2018.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128


Dr. MANI L. S.
(Managing Director.)
(DIN NO : 00825886)



Colinz

29-05-2018

Ref/Colinz/Results-Q4/2017-18
To,
Department of Corporate Services
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

BSE STOCK CODE NO : 531210

Dear Sir,

Sub: Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Declaration in respect of Audit Reports with un-modified opinion for the Financial Year ended 31st March 2018.

We hereby confirm and declare that the Statutory Auditors of the Company M/s. Vora & Associates, Chartered Accountants (Firm Registration No. 111612W) have issued the Audit Report with un-modified opinion in respect of Annual Audited Financial Results for the quarter and year ended 31st March 2018.

This is for your information and records.

Thanking you,

Yours faithfully,
FOR COLINZ LABORATORIES LTD


DR. MANI L.S.
MANAGING DIRECTOR
DIN: 00825886

Encl : as above

Colinz Laboratories Limited

CIN NO. L24200MH1986PLC041128